Immunic (IMUX) Reiterated at Buy by Stifel Post R&D Event

Stifel analyst Paul Matteis reiterated a Buy rating and $25.00 price target on Immunic Inc. (NASDAQ: IMUX).

The analyst commented, "In their R&D Event, IMUX mgmt was joined by Drs Bar-Or (UPenn, CHOP) and Krieger (Mt Sinai) to discuss the MS landscape and the VidoCa program. Highlights include: (1) KOLs emphasis around the residual unmet need in MS, especially PIRA--which even high-efficacy therapies don't address, (2) new preclinical data supporting VidoCa's Nurr1 activator properties and the neuroprotective benefits of this target, (3) mgmt's confidence on the upcoming ph3 ENSURE-1/2 readouts based on the positive ph2 RRMS data, and (4) IMUX's claims analysis showing favorable switching dynamics in MS and a very substantial number of patients that are promising targets for VidoCa. From our seat, we believe the commercial "bar" is low where Aubagio-like efficacy with clean safety (i.e., no liver tox, no alopecia, no embryotox) would garner meaningful uptake, as MS is a space that, commercially, has historically enabled multiple large commercial products with different patient niches based on preference."

For an analyst ratings summary and ratings history on Immunic Inc. click here. For more ratings news on Immunic Inc. click here.

Shares of Immunic Inc. closed at $12.19 yesterday.

You May Also Be Interested In

• Monolithic Power Systems (MPWR) Reiterated at Buy by Stifel on Reaching $4B Target
• J.Jill Inc. (JILL) PT Raised to $22 at TD Cowen
• BMO Capital on Envista Holdings Corp. (NVST): 'Better Execution, Higher Expectations'